Edwards Lifesciences (NYSE:EW) Upgraded at Robert W. Baird

Key Points

• Robert W. Baird upgraded Edwards Lifesciences to “outperform” from “neutral” and set a $116 price target, implying 16.72% upside from the stock’s current price.
• Edwards beat quarterly expectations, reporting adjusted EPS of $0.80 versus $0.74 forecast and revenue of $1.72 billion versus $1.68 billion; the company also raised its full-year outlook.
• Growth in transcatheter mitral and tricuspid therapies was strong, with sales up 44%, though rising competition in TAVR could pressure the company’s position in a key market.

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by Robert W. Baird from a "neutral" rating to an "outperform" rating in a report released on Thursday, Briefing.com reports. The brokerage currently has a $116.00 price target on the medical research company's stock. Robert W. Baird's price target suggests a potential upside of 16.72% from the stock's current price.

Several other equities research analysts also recently issued reports on the company. Wall Street Zen downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, October 31st. Royal Bank Of Canada lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Mizuho boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Finally, Rothschild & Co Redburn raised their target price on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the company a "buy" rating in a research note on Monday, July 27th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $104.08.

Edwards Lifesciences Trading Up 4.4%

Shares of Edwards Lifesciences stock opened at $99.39 on Thursday. The company has a market capitalization of $57.23 billion, a P/E ratio of 57.12, a price-to-earnings-growth ratio of 2.49 and a beta of 0.85. The stock has a fifty day simple moving average of $88.48 and a 200 day simple moving average of $85.61. Edwards Lifesciences has a 12-month low of $74.66 and a 12-month high of $100.25. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.06. The business had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.68 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm's quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences will post 3.00 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of the business's stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Andrew M. Dahl sold 544 shares of the business's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company's stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in Edwards Lifesciences in the second quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences during the second quarter valued at approximately $1,274,082,000. Bank of America Corp DE bought a new stake in Edwards Lifesciences in the second quarter worth $605,397,000. Deutsche Bank AG purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Edwards Lifesciences by 0.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company's stock valued at $496,503,000 after acquiring an additional 30,495 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80, topping the $0.74 consensus, and revenue of $1.72 billion versus expectations of $1.68 billion. Revenue grew year over year, while the company raised its full-year outlook and narrowed its 2026 forecast range. Q3 earnings, revenue and outlook
• Positive Sentiment: Truist Financial upgraded EW from “hold” to “strong-buy,” adding analyst support. Truist upgrade
• Positive Sentiment: Management highlighted strong momentum in its transcatheter mitral and tricuspid therapies business, with TMTT sales up 44%. Separately, trial results for the PASCAL tricuspid repair system showed better outcomes than medical therapy through one year, supporting the product’s potential. Q3 results and TMTT growth PASCAL trial results
• Negative Sentiment: CEO commentary acknowledged that more TAVR competition is coming, which could pressure Edwards’ position in a key market. RBC also said the Progress trial data is unlikely to meaningfully expand the transcatheter market, limiting the potential upside from that study. TAVR competition RBC assessment of Progress trial

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart's valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.